Serrano Alicia G, Pérez-Gil Jesús
Departamento de Bioquímica y Biología Molecular I, Facultad de Biología, Universidad Complutense, Jose Antonio Novais 2, Madrid, Spain.
Chem Phys Lipids. 2006 Jun;141(1-2):105-18. doi: 10.1016/j.chemphyslip.2006.02.017. Epub 2006 Mar 20.
Pulmonary surfactant is a lipid-protein complex, synthesized and secreted by the respiratory epithelium of lungs to the alveolar spaces, whose main function is to reduce the surface tension at the air-liquid interface to minimize the work of breathing. The activity of surfactant at the alveoli involves three main processes: (i) transfer of surface active molecules from the aqueous hypophase into the interface, (ii) surface tension reduction to values close to 0 mN/m during compression at expiration and (iii) re-extension of the surface active film upon expansion at inspiration. Phospholipids are the main surface active components of pulmonary surfactant, but the dynamic behaviour of phospholipids along the breathing cycle requires the necessary participation of some specific surfactant associated proteins. The present review summarizes the current knowledge on the structure, disposition and lipid-protein interactions of the hydrophobic surfactant proteins SP-B and SP-C, the two main actors participating in the surface properties of pulmonary surfactant. Some of the methodologies currently used to evaluate the surface activity of the proteins in lipid-protein surfactant preparations are also revised. Working models for the potential molecular mechanism of SP-B and SP-C are finally discussed. SP-B might act in surfactant as a sort of amphipathic tag, directing the lipid-protein complexes to insert and re-insert very efficiently into the air-liquid interface along successive breathing cycles. SP-C could be essential to maintain association of lipid-protein complexes with the interface at the highest compressed states, at the end of exhalation. The understanding of the mechanisms of action of these proteins is critical to approach the design and development of new clinical surfactant preparations for therapeutical applications.
肺表面活性物质是一种脂质-蛋白质复合物,由肺的呼吸上皮细胞合成并分泌到肺泡腔中,其主要功能是降低气液界面的表面张力,以最小化呼吸功。表面活性物质在肺泡处的活性涉及三个主要过程:(i)表面活性分子从水相下层转移到界面;(ii)在呼气时压缩过程中表面张力降低至接近0 mN/m的值;(iii)在吸气时扩张时表面活性膜重新伸展。磷脂是肺表面活性物质的主要表面活性成分,但磷脂在呼吸周期中的动态行为需要一些特定的表面活性物质相关蛋白的必要参与。本综述总结了关于疏水性表面活性蛋白SP-B和SP-C的结构、分布以及脂质-蛋白质相互作用的当前知识,这两种蛋白是参与肺表面活性物质表面性质的两个主要因素。还对目前用于评估脂质-蛋白质表面活性物质制剂中蛋白质表面活性的一些方法进行了修订。最后讨论了SP-B和SP-C潜在分子机制的工作模型。SP-B可能在表面活性物质中起一种两亲性标签的作用,引导脂质-蛋白质复合物在连续的呼吸周期中非常有效地插入和重新插入气液界面。在呼气末期,SP-C对于维持脂质-蛋白质复合物在最高压缩状态下与界面的结合可能至关重要。了解这些蛋白质的作用机制对于开发用于治疗应用的新型临床表面活性物质制剂的设计和开发至关重要。